Phase II Study of QLC2519 in Pediatric Solid Tumor Participants

QLC2519 (Mai Li Sheng®) is a new protein drug created by fusing the N-terminal of highly active modified G-CSF with the C-terminal of HSA. The modified G-CSF retained high activity while reducing affinity for the G-CSF receptor, which can significantly inhibit the the G-CSF receptor-mediated (RMC) pathway. The aim of this study is to evaluate the PK/PD characteristics of QLC2519 in preventing chemotherapy-induced neutropenia (CIN) in children with sarcoma.

NCT Number	NCT07724756
Lead Sponsor	Qilu Pharmaceutical Co., Ltd.
Conditions	Pediatric Malignant Solid Tumor, Febrile Neutropenia (FN), Neutropenia
Enrollment	18 participants
Start Date	2026-06-26
Primary Completion	2027-06-26 (estimated)
Study Completion	2028-06-26 (estimated)
Updated on ClinicalTrials.gov	2026-07-24